Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02036463

A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD) Clinical Trial

Official title:
CINRG0513: A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy

Clinical Trial Summary

Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disease for which no curative treatment has yet been identified, making it important to slow progression and improve the quality of life among affected boys and young men. Treatment with corticosteroids is standard of care for patients with DMD five years old and older, due to the robust observation that this intervention lengthens the interval prior to loss of ambulation but is associated with many side effects. This clinical trial will be conducted in the youngest age group able to receive corticosteroids orally and on whom study outcomes are measurable, ages 3 to 7 years. This is a randomized, double blinded, double masked, placebo-controlled clinical trial that will explore whether better synchronization of corticosteroid administration with the circadian rhythm will provide improved tolerability and at least comparable efficacy to current standards in which corticosteroids are always given in the morning. Furthermore, the trial provides a unique opportunity to rigorously evaluate corticosteroid effects in the young DMD patient, both for efficacy as compared to placebo and as a study of the impact of corticosteroid chronotherapy, or delayed release, on increased tolerability over standard therapy. The main hypothesis is that synchronization of the timing of corticosteroid dosing will improve medication tolerability in children, while maintaining (non-inferiority) the efficacy of corticosteroid. The study also offers a unique opportunity to measure several biomarkers as well as novel genetic modifiers that may further impact the response to corticosteroid in DMD.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02036463
Study type Interventional
Source Ann & Robert H Lurie Children's Hospital of Chicago
Contact
Status Withdrawn
Phase Phase 2
Start date November 2014
Completion date February 2015
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02814019 - A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids Phase 3
Completed NCT01478022 - To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20 Phase 1
Completed NCT00654784 - Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy Phase 2
Recruiting NCT02614820 - The Safety, Efficacy and Tolerability of Remote Ischemic Preconditioning as a Therapy to DMD N/A
Completed NCT02255552 - Study of Eteplirsen in DMD Patients Phase 3
Completed NCT01982695 - Cardiomyopathy in DMD: Lisinopril vs. Losartan N/A
Recruiting NCT05516745 - E-monitoring of PULMonary Function in Patients With Duchenne Muscular Dystrophy at Home" N/A
Completed NCT02420379 - Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy Phase 2
Active, not recruiting NCT05135663 - Extension Study of NS-089/NCNP-02 in DMD Phase 2
Completed NCT01380964 - Research of Biomarkers in Duchenne Muscular Dystrophy Patients N/A
Completed NCT05990608 - Peabody Developmental Motor Scaling In Children With Period Duchenne Muscular Dystrophy
Recruiting NCT04322357 - Twice Weekly Steroids and Exercise as Therapy for DMD Phase 2
Not yet recruiting NCT06392724 - A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy. Early Phase 1
Completed NCT01540409 - Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy Phase 2
Terminated NCT04184882 - A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD) Phase 1
Terminated NCT04254172 - A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy
Recruiting NCT05524883 - Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Phase 1/Phase 2
Completed NCT01761292 - A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD Phase 1/Phase 2